报价延迟最少15分钟:2025/10/23 16:29 EDT
盘后时段
|
||||
|
1.49 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.49
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.06/-0.39
|
|
企业价值
99.76M
|
| 资产负债 |
|
每股账面净值
0.23
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
69.30M
|
|
每股收益
1.24
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/10/23 16:29 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| TELA Bio Inc a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. |
